SRx Health's Quiet 4.99% Bet on SmartKem: Strategic Lifeline or Speculative Gamble on a Company Questioning Its Own Survival?
Shares of SmartKem (SMTK) doubled on June 8 after a little-known digital-asset treasury firm bought a near-5% stake in the sub-dollar advanced-materials company — raising the question of whether this is a genuine catalyst or just a headline-driven squeeze in one of Nasdaq's thinnest stocks.
A Crypto-Treasury Outfit Made a Bet Worth Watching — and Worrying About
SRx Health Solutions and its pending merger partner, EMJ Crypto Technologies — a digital-asset treasury platform — announced a 4.99% equity stake in SmartKem through a shelf takedown , a mechanism where pre-registered shares are sold off to raise quick cash. They also purchased convertible preferred securities through a non-brokered private placement , meaning those preferred shares could eventually convert into common stock, diluting existing holders further. The companies didn't disclose how much they invested.
The Buyer Itself Has Serious Red Flags
SRx Health has been notified by NYSE American of listing deficiencies related to stockholders' equity and historical losses, and was granted an extension to mid-2026 to regain compliance.
In February 2026, SRx received a public warning letter from NYSE for violating listing rules after issuing roughly 7.5 million shares without proper approval. SRx trades at roughly $0.12 with a $71 million market cap driven by ~590 million shares outstanding. A buyer with its own survival questions isn't the institutional validation bulls would want.
SmartKem's Fundamentals Remain Dire
In its first-quarter filing, SmartKem said there was "substantial doubt" it could keep operating as a going concern.
The company reported $7.6 million in cash as of March 31 — not enough to cover a year of costs.
Trailing revenue is just $697,000 against net losses of $10.5 million.
Nasdaq gave SmartKem until September 1 to hold its stock above $1 for ten straight trading days or face delisting.
The 100% Pop May Be Noise, Not Signal
Trading volume hit 102.6 million shares on June 8 — nearly four times the average. With only 21.4 million shares outstanding , that implies frenzied turnover in a stock with a pre-surge market cap under $9 million. The bigger question is whether the SRx stake delivers anything beyond a quick squeeze in a stock still trading under Nasdaq's minimum, linked to a company openly saying it needs more funding. Convertible preferred securities add another layer of potential dilution. Until SmartKem shows a credible path to revenue or secures its listing, the rally looks fragile.